Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer

Daniel Chan, Yun Zheng, Jeffrey Tyner, Wee Joo Chng, Wen Wen Chien, Sigal Gery, Geraldine Leong, Glenn D. Braunstein, H. Phillip Koeffler

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines. Methods: The anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn ®). Results: Belinostat and panobinostat were active against the thyroid cancer cell lines irrespective of their mutational composition, and belinostat was effective in preventing growth of human thyroid cancer xenografts in immunodeficient mice. Further studies showed that both HDACIs induced apoptosis. HDACI also elevated acetylated histone 3, p21Waf, and PARP, and decreased levels of phosphorylated ERK and AKT (Ser473). RNA assay analysis suggested both HDACIs modulated genes associated with the cell cycle, DNA damage and apoptosis. Most of the TKI (pazopanib, motesanib, sorafenib and dasatinib) were either inactive in vitro or were active only at high doses. However, the novel combinations of either pazopanib or dasatinib TKIs with either belinostat or panobinostat synergistically inhibited cell growth of thyroid cancer cells in vitro. Conclusions: In summary, these HDACIs either alone or combined with selected TKIs may have a role in treatment of aggressive thyroid cancer.

Original languageEnglish (US)
Pages (from-to)1507-1514
Number of pages8
JournalJournal of Cancer Research and Clinical Oncology
Volume139
Issue number9
DOIs
StatePublished - Sep 2013

Fingerprint

Histone Deacetylase Inhibitors
Thyroid Neoplasms
Protein-Tyrosine Kinases
Apoptosis
Cell Line
Microarray Analysis
Growth
panobinostat
In Vitro Techniques
belinostat
Heterografts
Histones
DNA Damage
Cell Cycle
RNA
Therapeutics
Genes

Keywords

  • Histone deacetylases
  • Novel therapeutic approach
  • Thyroid cancer
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Belinostat and panobinostat (HDACI) : In vitro and in vivo studies in thyroid cancer. / Chan, Daniel; Zheng, Yun; Tyner, Jeffrey; Chng, Wee Joo; Chien, Wen Wen; Gery, Sigal; Leong, Geraldine; Braunstein, Glenn D.; Koeffler, H. Phillip.

In: Journal of Cancer Research and Clinical Oncology, Vol. 139, No. 9, 09.2013, p. 1507-1514.

Research output: Contribution to journalArticle

Chan, D, Zheng, Y, Tyner, J, Chng, WJ, Chien, WW, Gery, S, Leong, G, Braunstein, GD & Koeffler, HP 2013, 'Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer', Journal of Cancer Research and Clinical Oncology, vol. 139, no. 9, pp. 1507-1514. https://doi.org/10.1007/s00432-013-1465-6
Chan, Daniel ; Zheng, Yun ; Tyner, Jeffrey ; Chng, Wee Joo ; Chien, Wen Wen ; Gery, Sigal ; Leong, Geraldine ; Braunstein, Glenn D. ; Koeffler, H. Phillip. / Belinostat and panobinostat (HDACI) : In vitro and in vivo studies in thyroid cancer. In: Journal of Cancer Research and Clinical Oncology. 2013 ; Vol. 139, No. 9. pp. 1507-1514.
@article{735bfc73b2dd4987985ffd543702042d,
title = "Belinostat and panobinostat (HDACI): In vitro and in vivo studies in thyroid cancer",
abstract = "Purpose: Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines. Methods: The anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn {\circledR}). Results: Belinostat and panobinostat were active against the thyroid cancer cell lines irrespective of their mutational composition, and belinostat was effective in preventing growth of human thyroid cancer xenografts in immunodeficient mice. Further studies showed that both HDACIs induced apoptosis. HDACI also elevated acetylated histone 3, p21Waf, and PARP, and decreased levels of phosphorylated ERK and AKT (Ser473). RNA assay analysis suggested both HDACIs modulated genes associated with the cell cycle, DNA damage and apoptosis. Most of the TKI (pazopanib, motesanib, sorafenib and dasatinib) were either inactive in vitro or were active only at high doses. However, the novel combinations of either pazopanib or dasatinib TKIs with either belinostat or panobinostat synergistically inhibited cell growth of thyroid cancer cells in vitro. Conclusions: In summary, these HDACIs either alone or combined with selected TKIs may have a role in treatment of aggressive thyroid cancer.",
keywords = "Histone deacetylases, Novel therapeutic approach, Thyroid cancer, Tyrosine kinase inhibitors",
author = "Daniel Chan and Yun Zheng and Jeffrey Tyner and Chng, {Wee Joo} and Chien, {Wen Wen} and Sigal Gery and Geraldine Leong and Braunstein, {Glenn D.} and Koeffler, {H. Phillip}",
year = "2013",
month = "9",
doi = "10.1007/s00432-013-1465-6",
language = "English (US)",
volume = "139",
pages = "1507--1514",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Belinostat and panobinostat (HDACI)

T2 - In vitro and in vivo studies in thyroid cancer

AU - Chan, Daniel

AU - Zheng, Yun

AU - Tyner, Jeffrey

AU - Chng, Wee Joo

AU - Chien, Wen Wen

AU - Gery, Sigal

AU - Leong, Geraldine

AU - Braunstein, Glenn D.

AU - Koeffler, H. Phillip

PY - 2013/9

Y1 - 2013/9

N2 - Purpose: Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines. Methods: The anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn ®). Results: Belinostat and panobinostat were active against the thyroid cancer cell lines irrespective of their mutational composition, and belinostat was effective in preventing growth of human thyroid cancer xenografts in immunodeficient mice. Further studies showed that both HDACIs induced apoptosis. HDACI also elevated acetylated histone 3, p21Waf, and PARP, and decreased levels of phosphorylated ERK and AKT (Ser473). RNA assay analysis suggested both HDACIs modulated genes associated with the cell cycle, DNA damage and apoptosis. Most of the TKI (pazopanib, motesanib, sorafenib and dasatinib) were either inactive in vitro or were active only at high doses. However, the novel combinations of either pazopanib or dasatinib TKIs with either belinostat or panobinostat synergistically inhibited cell growth of thyroid cancer cells in vitro. Conclusions: In summary, these HDACIs either alone or combined with selected TKIs may have a role in treatment of aggressive thyroid cancer.

AB - Purpose: Advanced thyroid cancer responds poorly to most therapies. New therapies and combinations are needed. The aim of this study was to examine both in vitro and in vivo activity of two relatively new histone deacetylase inhibitors (HDACIs), belinostat and panobinostat, and a variety of tyrosine kinase inhibitors (TKIs) against a panel of nine human thyroid cancer cell lines. Methods: The anti-proliferative activity and the effects of HDACIs, TKIs and their combinations on thyroid cancer cells were determined by cytotoxicity assays, microarray and immunoblot analyses. Synergism between HDACIs and TKIs was assessed by the median effects model of Chou-Talalay (Calcusyn ®). Results: Belinostat and panobinostat were active against the thyroid cancer cell lines irrespective of their mutational composition, and belinostat was effective in preventing growth of human thyroid cancer xenografts in immunodeficient mice. Further studies showed that both HDACIs induced apoptosis. HDACI also elevated acetylated histone 3, p21Waf, and PARP, and decreased levels of phosphorylated ERK and AKT (Ser473). RNA assay analysis suggested both HDACIs modulated genes associated with the cell cycle, DNA damage and apoptosis. Most of the TKI (pazopanib, motesanib, sorafenib and dasatinib) were either inactive in vitro or were active only at high doses. However, the novel combinations of either pazopanib or dasatinib TKIs with either belinostat or panobinostat synergistically inhibited cell growth of thyroid cancer cells in vitro. Conclusions: In summary, these HDACIs either alone or combined with selected TKIs may have a role in treatment of aggressive thyroid cancer.

KW - Histone deacetylases

KW - Novel therapeutic approach

KW - Thyroid cancer

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84882584727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882584727&partnerID=8YFLogxK

U2 - 10.1007/s00432-013-1465-6

DO - 10.1007/s00432-013-1465-6

M3 - Article

C2 - 23824064

AN - SCOPUS:84882584727

VL - 139

SP - 1507

EP - 1514

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

IS - 9

ER -